A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis
Status:
Completed
Trial end date:
2018-12-21
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of tezacaftor in combination with ivacaftor (TEZ/IVA)
in participants with cystic fibrosis (CF) aged 6 through 11 years, who are homozygous for the
F508del mutation (F/F) or heterozygous for F508del with an eligible residual function
mutation (F/RF).